Human TWEAK/TNFSF12 DuoSet ELISA Summary
* Provided that the recommended microplates, buffers, diluents, substrates and solutions are used, and the assay is run as summarized in the Assay Procedure provided.
Product Features
- Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time
- Development protocols are provided to guide further assay optimization
- Assay can be customized to your specific needs
- Economical alternative to complete kits
Kit Content
- Capture Antibody
- Detection Antibody
- Recombinant Standard
- Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)
Other Reagents Required
PBS: (Catalog # DY006), or 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2 - 7.4, 0.2 µm filtered
Wash Buffer: (Catalog # WA126), or equivalent
Reagent Diluent: 1% BSA in PBS, pH 7.2-7.4, 0.2 m filtered (R&D Systems Catalog # DY995). Quality of BSA is critical (see Technical Hints).
Blocking Buffer: 1% BSA in PBS, pH 7.2-7.4, 0.2 m filtered (R&D Systems Catalog # DY995). Quality of BSA is critical (see Technical Hints).
Substrate Solution: 1:1 mixture of Color Reagent A (H2O2) and Color Reagent B (Tetramethylbenzidine) (Catalog # DY999)
Stop Solution: 2 N H2SO4 (Catalog # DY994)
Microplates: R&D Systems (Catalog # DY990), or equivalent
Plate Sealers: ELISA Plate Sealers (Catalog # DY992), or equivalent
Scientific Data
Product Datasheets
Preparation and Storage
Background: TWEAK/TNFSF12
TWEAK is a type II transmembrane protein belonging to the TNF superfamily. The extracellular domains of human and mouse TWEAK share 89% amino acid sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecule by proteolytic cleavage after Arg 93, suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells.
Assay Procedure
GENERAL ELISA PROTOCOL
Plate Preparation
- Dilute the Capture Antibody (to the working concentration stated in the product datasheet ) in PBS without carrier protein. Immediately coat a 96-well microplate with 100 µL per well of the diluted Capture Antibody. Seal the plate and incubate overnight at room temperature.
- Aspirate each well and wash with Wash Buffer, repeating the process two times for a total of three washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential for good performance. After the last wash, remove any remaining Wash Buffer by aspirating or by inverting the plate and blotting it against clean paper towels.
- Block each well of the microplate as recommended in the product datasheet. Incubate at room temperature for a minimum of 1 hour.
Note: The recommended Reagent Diluent typically contains 1% BSA. Some DuoSet Development Kits require alternative blocking agents, or for plates to be blocked overnight with a higher percentage of BSA, please see the product datasheet for details.
- Repeat the aspiration/wash as in step 2. The plates are now ready for sample addition.
PRECAUTION
The Stop Solution suggested for use with this kit is an acid solution. Wear eye, hand, face and clothing protection when using this material.
Assay Procedure
- Add 100 µL of sample or standards in Reagent Diluent, or an appropriate diluent, per well. Cover with an adhesive strip and incubate 2 hours at room temperature.
- Repeat the aspiration/wash as in step 2 of Plate Preparation.
- Add 100 µL of the Detection Antibody, diluted in Reagent Diluent (as recommended in the product datasheet), to each well. Cover with a new adhesive strip and incubate 2 hours at room temperature.
- Repeat the aspiration/wash as in step 2 of Plate Preparation.
- Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the plate and incubate for 20 minutes at room temperature. Avoid placing the plate in direct light.
- Repeat the aspiration/wash as in step 2.
- Add 100 µL of Substrate Solution to each well. Incubate for 20 minutes at room temperature. Avoid placing the plate in direct light.
- Add 50 µL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing.
- Determine the optical density of each well immediately, using a microplate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.
Citations for Human TWEAK/TNFSF12 DuoSet ELISA
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
15
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Effects of an Intervention with Selenium and Coenzyme Q10 on Five Selected Age-Related Biomarkers in Elderly Swedes Low in Selenium: Results That Point to an Anti-Ageing Effect-A Sub-Analysis of a Previous Prospective Double-Blind Placebo-Controlled Randomised Clinical Trial
Authors: Alehagen, U;Alexander, J;Aaseth, JO;Larsson, A;Svensson, E;Opstad, TB;
Cells
Species: Human
Sample Types: Plasma
-
Serum Levels of the Cytokine TWEAK Are Associated with Metabolic Status in Patients with Prostate Cancer and Modulate Cancer Cell Lipid Metabolism In Vitro
Authors: A Altuna-Coy, X Ruiz-Plaza, M Alves-Sant, J Segarra-To, MR Chacón
Cancers, 2021-09-18;13(18):.
Species: Human
Sample Types: Serum
-
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy
Authors: S Piantoni, F Regola, S Masneri, M Merletti, T Lowin, P Airò, A Tincani, F Franceschi, L Andreoli, G Pongratz
Frontiers in Pharmacology, 2021-05-21;12(0):666971.
Species: Human
Sample Types: Serum
-
Liquid Biopsy-Based Exo-oncomiRNAs Can Predict Prostate Cancer Aggressiveness
Authors: X Ruiz-Plaza, A Altuna-Coy, M Alves-Sant, J Vila-Barja, JF García-Fon, S Martínez-G, J Segarra-To, MR Chacón
Cancers, 2021-01-11;13(2):.
Species: Human
Sample Types: Semen
-
Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis
Authors: H Wang, S Wang, L Li, X Wang, C Liu, M Lu, Y Xia, Y Liu
Cytokine, 2020-12-08;138(0):155391.
Species: Human
Sample Types: Serum
-
Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness
Authors: X Ruiz-Plaza, E Rodríguez-, M Alves, A Altuna-Coy, J Lozano-Bar, M Portero-Ot, JF García-Fon, S Martínez-G, J Segarra, MR Chacón
J Transl Med, 2019-09-09;17(1):307.
Species: Human
Sample Types: Serum
-
Soluble CD163 and TWEAK in early pregnancy gestational diabetes and later glucose intolerance
Authors: J Dereke, J Nilsson, C Nilsson, H Strevens, M Landin-Ols, M Hillman
PLoS ONE, 2019-05-09;14(5):e0216728.
Species: Human
Sample Types: Plasma
-
Effect of influenza vaccine on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in older adults
Authors: M Keshtkar-J, M Ouyang, M Keshtkarja, S Almed, H Li, JD Walston, R Rios, SX Leng
Vaccine, 2018-03-13;0(0):.
Species: Human
Sample Types: Serum
-
Synovial fluid levels of TWEAK and matrix metalloproteinase 1 in patients with osteoarthritis, and associations with disease severity
Authors: IY Hwang, YS Youm, SD Cho, SW Choi, MH Bae, SJ Park, HW Kim
J Orthop Surg (Hong Kong), 2018-01-01;26(1):2309499018760.
Species: Human
Sample Types: Synovial Fluid
-
Evaluation of interleukin-2, interleukin-8, and tumor necrosis factor-like weak inducer of apoptosis in hemodialysis and renal transplant patients and healthy controls
Authors: Nasar Alwahaibi
Saudi J Kidney Dis Transpl, 2016-11-01;27(6):1123-1128.
Species: Human
Sample Types: Serum
-
TWEAK/Fn14 system and crescent formation in IgA nephropathy.
Authors: Sasaki Y, Shimizu Y, Suzuki Y, Horikoshi S, Tomino Y
BMC Nephrol, 2015-03-14;16(0):27.
Species: Human
Sample Types: Serum
-
Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.
Authors: Rojo-Martinez G, Maymo-Masip E, Rodriguez M, Solano E, Goday A, Soriguer F, Valdes S, Chaves F, Delgado E, Colomo N, Hernandez P, Vendrell J, Chacon M
PLoS ONE, 2014-06-30;9(6):e101250.
Species: Human
Sample Types: Serum
-
Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk.
Authors: Diaz-Lopez A, Bullo M, Chacon M, Estruch R, Vendrell J, Diez-Espino J, Fito M, Corella D, Salas-Salvado J
Cardiovasc Diabetol, 2014-02-24;13(0):51.
Species: Human
Sample Types: Serum
-
Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.
Authors: Gaudineau B, Fougere M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S
J Cell Sci, 2012-07-05;125(0):4475-86.
Species: Human
Sample Types: Cell Culture Supernates
-
Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura.
Authors: Chen T, Guo ZP, Li MM, Li JY, Jiao XY, Zhang YH, Liu HJ
Clin. Exp. Immunol., 2011-07-15;166(1):64-71.
Species: Human
Sample Types: Serum
FAQs
No product specific FAQs exist for this product, however you may
View all ELISA FAQsReviews for Human TWEAK/TNFSF12 DuoSet ELISA
Average Rating: 4.3 (Based on 3 Reviews)
Have you used Human TWEAK/TNFSF12 DuoSet ELISA?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by: